HIV Infections Clinical Trial
To evaluate factors influencing the risk of transfusion-transmitted human immunodeficiency virus (HIV) infection and its progression to clinically significant manifestations.
BACKGROUND:
In the summer of 1981, the Centers for Disease Control (CDC) alerted the medical community
to an unexpected outbreak of Pneumocystis carinii pneumonia and Kaposi's sarcoma in young
homosexual men, individuals not known to be at risk for these uncommon diseases. Studies of
immunologic functions in these patients demonstrated lymphopenia, cutaneous anergy, reduced
helper T-lymphocyte (T4) subpopulations, depressed ratios of helper T-lymphocytes to
suppressor T-lymphocytes (T4:T8), abnormal lymphocyte responses to mitogen stimulation,
decreased natural killer-cell activity, and often hypergammaglobulinemia. The name of
acquired immunodeficiency syndrome (AIDS) was given to this disorder of immunologic
regulation with opportunistic infections or Kaposi's sarcoma or both.
Since that time, AIDS was reported in patients with hemophilia and in others receiving blood
transfusions. The NHLBI was delegated responsibility for studies to elucidate, through a
systematic prospective study, the possible association of blood product use with AIDS. The
incidence of transfusion-acquired AIDS was so low as to preclude a general prospective study
of transfusion recipients to determine the overall incidence of the disease. By focusing on
patient groups that appeared to have a higher likelihood for developing AIDS because they
required chronic, repeated transfusion therapy, information about the epidemiology of the
disorder could be more readily obtained. Continuing medical evaluation of these patients
from apparent high-risk groups in a prospective fashion allowed identification of
significant emerging physiologic alterations and to follow the time-course of pathologic
developments.
The purpose of this study was to develop a clear picture of what immunologic changes
occurred in patients who were transfused and to determine when these changes occurred and
how long they lasted. Since most of the patient population was heavily transfused, some of
the study subjects eventually developed AIDS. Information obtained during the study about
these patients was then used to answer such questions as: Which factors determined a
particular person's risk of developing AIDS and to what degree? What alterations occurred
before the clinical manifestations of AIDS? Was progression from normal to defective
cell-mediated immunity to AIDS strictly unidirectional or did altered cell-mediated immunity
in the study cohort ever regress to normality? If progression was not unidirectional, what
determined the outcome? Also, the importance of establishing a serum and cell repository
could not be overemphasized, since, as new scientific information became available, these
specimens enabled the performance of a number of different retrospective studies.
In 1984 a serum repository for HIV testing was established. The task of the repository was
to collect and store serum samples from blood donors in four blood transfusion units located
in four major risk areas for AIDS, namely New York, San Francisco, Miami, and Los Angeles.
Blood was obtained from the New York Blood Center in New York City, the Irwin Memorial Blood
Bank in San Francisco, the Red Cross in Los Angeles, and the American Red Cross, South
Florida Region, in Miami. The purpose of the repository was to determine the outcome of the
transfusion of blood components retrospectively found to show HIV infection of the donor.
The collected sera were separated, indexed, frozen, and stored.
In 1984 the second part of the Transfusion Safety Study, the prospective study, was
initiated by NHLBI under a separate request for proposal. The testing of the 201,000 serum
specimens in the donor repository for antibody to HIV was carried out by laboratories in the
prospective study. Those donors confirmed to be anti-HIV positive and matching donors
confirmed to be anti-HIV negative were recruited as TSS subjects. Recipients of blood from
the positive donors and the negative donors were also recruited as subjects.
In September 1984, the TSS began a nine month planning phase during which the protocols and
data systems for the prospective study were developed. Subjects were entered in July 1985
through June 1989. Analysis continued through November 1997. There were clinical centers in
Los Angeles, San Francisco, New York City, and Miami. The coordinating center was at the
University of Southern California. The central laboratories including the immunological
standardization laboratory, the immunological reagents laboratory, and the central
processing laboratory were located in Los Angeles, with one of the immunology laboratories
located in Seattle, Washington at the Puget Sound Blood Center.
DESIGN NARRATIVE:
At baseline, each subject received a physical examination, was questioned as to medical
history, and gave blood samples for immunologic and other studies. Each subject returned at
a specified interval for a repeat of studies specified in the protocol. Blood studies
included complete blood cell count, characterization of immunologic cells such as T- and
B-lymphocytes and natural killer-cells. Plasma and Buffy coat cell suspensions were stored
frozen. Alanine aminotransferase levels were determined. Serologic tests were performed for
hepatitis, Epstein-Barr virus, and cytomegalovirus. Markers of immune status, including
immune globulin levels were measured. The study ended in November, 1997.
;
N/A
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |